Search the Newsreel

Bio-Rad (BIO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 5 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Ruben ArguetaChief Executive Officer - Norman SchwartzPresident and Chief Operating Officer - Jonathan DiVincenzoExecutive Vice President and Chief Financial Officer - Roop Lakkaraju …

LongBio Pharma Sets August Board Meeting to Approve Interim Results and Mull Dividend

Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock

Have you assessed how the international operations of Bio-Rad Laboratories (BIO) performed in the quarter ended June 2026? For this maker of instruments used in biomedical research, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its …

Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Q2 earnings and new guidance put Bio-Rad Laboratories in focus Bio-Rad Laboratories (BIO) drew investor attention after reporting second quarter 2026 results alongside …

Bio-Rad Laboratories, Inc. $BIO Shares Bought by California State Teachers Retirement System

The California State Teachers Retirement System increased its stake in Bio-Rad Laboratories (NYSE:BIO) by 22.9% in the first quarter, now owning 21,932 shares worth $6.1 million. Bio-Rad Laboratories recently reported strong Q2 adjusted earnings of $2.62 per share, exceeding analyst estimates, although revenue was …

Bio Rad Laboratories (BIO) Stock Jumps As ddPCR Progress Meets Flat Demand

Bio-Rad Laboratories' stock saw a 4.5% jump following its Q2 2026 earnings report, with revenue of US$651 million and non-GAAP EPS of US$2.62, broadly flat year-over-year. The company's digital PCR (ddPCR) revenue grew 6% with instrument sales up over 20%, supporting a "bull case" …

Bio-Rad Laboratories (NYSE:BIO) Sets New 52-Week High on Earnings Beat

Bio-Rad Laboratories Q2 Earnings Call Highlights

Bio-Rad forecasts 2026 currency-neutral revenue growth of (-3%) to +0.5% while targeting $30M-$35M net cost savings by end of 2027

Earnings Call Insights: Bio-Rad Laboratories (BIO) Q2 2026 MANAGEMENT VIEW * "Total company revenue in the second quarter was approximately $651 million, essentially flat as reported and down 1.9% on a currency-neutral basis compared with the prior year" (President & COO Jonathan DiVincenzo). * …

Bio-Rad Laboratories (BIO) Stock Falls on Q2 2026 Earnings

Bio-Rad Laboratories (NYSE:BIO) Releases Earnings Results, Beats Estimates By $0.87 EPS

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.34 per share. This compares to earnings of $2.61 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Bio-Rad Laboratories (NYSE: BIO) exec vests 246 RSUs, withholds shares

Eva Anette Engelhardt, EVP and President, CDG of Bio-Rad Laboratories (NYSE: BIO), had 246 Restricted Stock Units vest on July 25, 2026. To cover tax obligations, 89 shares were withheld at a price of $314.46 per share. After this transaction, she holds 492 remaining …

Bio-Rad Laboratories (BIO) to Release Earnings on Thursday